Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the Cereva Biologics Inc. 2023 Third Quarter Operational Highlights and Financial Results. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star then zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Shelcross. Thank you. You may begin. Thank you, Irene, and good morning, everyone, and thank you for joining our call today. Welcome to Threva Biologics' third quarter 2023 investor conference call. Joining me on today's call will be Dr. Manal Kaskal, Director General of Threva Biologics, European subsidiary, and Dr. Vince Wager, Head of Corporate and Product Development of Threva Biologics. Theriva Biologics issued a press release this morning, which provided operational highlights and included the financial results for the third quarter ended September 30, 2023. The press release can be found in the investor section of the company website at www.therivabio.com, together with the quarterly report on Form 10-Q for the quarter ended September 30, 2023, which we plan to file today with the Securities and Exchange Commission. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company's website, www.thrivabio.com, for 90 days. During this call, certain forward-looking statements regarding Thriva Biologics and VCN Biosciences' current expectations and projections about future events will be made. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and s...